Biotech company Moderna, which developed one of the two most effective COVID-19 vaccines last year, plans to begin human trials soon for a new AIDS vaccine, according to multiple news sources.According to information posted last week to the National Institute of Health’s clinical trial database, Moderna is looking for 56 HIV-negative people, ages 18-50, to participate in the trials set to begin this week (Thursday, Aug.
19) and conclude in the spring of 2023. Moderna’s AIDS vaccines passed through Phase 1 testing for safety, involving just a few human volunteers, earlier this year.
Phase II will test the vaccine’s efficacy as compared to other preventative treatments now available, such as PrEP. Unlike live or inactive vaccines, mRNA